Richard Kapsa

Next week, Bio€quity Europe, hosted by @BioCentury and @EBDgroup, takes center stage in our hometown. In addition to participation in the CEO’s discussion panel, Radek Spisek will present recent progress across our development pipeline of next generation #ADCs and immunocytokines on Tuesday, May 5th. If you’re interested in connecting please reach out to: partnering@sotio.com and our team attending, Radek Spisek, Norbert Prenzel, Martin Vodak or @RichardKapsa. #BioEquityEurope #DrugDevelopment #OncologyResearch #BiotechPartnering

Radek Spisek, CEO, and Norbert Prenzel, Head of Business Development, are heading to San Diego, CA, for the upcoming @AACR Annual Meeting. As we rapidly expand our clinical pipeline with next-generation #ADCs, we look forward to connecting with partners and investors to explore new opportunities for collaboration. If you’re attending and would like to meet, please reach out. #AACR2026 #BiotechPartnering #OncologyInnovation

#ColorectalCancer is now the leading cause of cancer-related death among people younger than 50 in the U.S. It’s a critical moment for #ColorectalCancerAwarenessMonth to spread the word and help drive earlier diagnosis and treatment. We’re developing SOT109, a next generation #ADC designed to target CDH17, an antigen that is highly expressed in colorectal cancer and other GI cancers. Check out how ADCs like our SOT109 program work to address cancers like colorectal cancer below. Learn more about colorectal cancer’s rise in the @AmericanCancer recent report: pressroom.cancer.org/under-50-morta… #DrugDevelopment #AntibodyDrugConjugates

In the article below, Chief Scientific Officer, Amy Jensen-Smith, shares her perspective on the urgent unmet need in #sarcoma and why advancing researching in this complex disease area is so critical, especially on #RareDiseaseDay. SOTIO is committed to developing precision-based therapies for sarcoma, exemplified through SOT106, our investigational antibody-drug conjugate (#ADC) targeting LRRC15, a clinically validated target broadly expressed across sarcoma subtypes. 👉 linkedin.com/posts/amy-jens… #RareDiseaseDay2026 #RareDiseases #RareCancers #OncologyDevelopment

This May, Bio€quity Europe, organized by @BioCentury and #EBDGroup, heads to Prague for its 26th year. We’re thrilled to welcome the biotech community to our home city. We’ll be meeting fellow #oncology experts and showcasing how our emerging pipeline, including our #ADC programs, is turning cutting-edge science into new treatment options for difficult-to-treat solid tumors. We’re eager to engage with those shaping this next wave of innovation. Learn more about this year’s event here: conferences.biocentury.com/bioequity-euro… #BIOEquityEurope #DrugDevelopment #CancerResearch

Today, we celebrate #InternationalDayOfWomenAndGirlsInScience. At SOTIO, women scientists play an essential role across our organization, from discovery research to translational and preclinical development for #cancer treatments. Their perspectives, leadership, and commitment are pivotal to advancing innovative, patient-focused therapies and turning scientific insight into real-world impact. Their work helps move promising science forward and brings us closer to delivering meaningful new treatment options for patients. #WomenInScience #WomenInSTEM #CancerResearch #DrugDevelopment

#WorldCancerDay reminds us of the importance of innovation and collaboration in advancing care for patients everywhere. SOTIO is committed to developing novel therapies for patients with #solidtumors, including next-generation #ADCs like SOT106 for the treatment of soft tissue sarcoma and osteosarcoma and SOT109 for the treatment of colorectal and GI cancers. By creating more precise and effective treatment options, we aim to improve outcomes and expand possibles for those living with cancer. Learn more about our work here: sotio.com/pipeline/sotio… #CancerResearch #OncologyInnovation #DrugDevelopment #UnitedByUnique

We are excited to share this collaborative publication in @NaturePortfolioCommunications, led by our partners at the @UniBasel_en alongside the SOTIO research team. The study shows that ovarian cancer dramatically alters the omentum, a fatty tissue in the abdomen, when it spreads there. By mapping individual cells in healthy and cancer-affected tissue, researchers found that the cancer reprograms the omentum to support tumor growth. We thank our academic collaborators and all contributing institutions for their scientific excellence and dedication in advancing cancer research: @UniSpitalBasel, @ETH_en, @ISBSIB, @CharlesUniPRG Read the full text here: pubmed.ncbi.nlm.nih.gov/41397972/ #OncologyResearch #OvarianCancer